B+
Bull case
20%
Probability
Target price
$120.00
+130.7% vs current
CRSP
CRISPR TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$69.00
+32.6% vs current
B-
Bear case
20%
Probability
Target price
$35.00
-32.7% vs current
AI sentiment snapshot
Latest data as of 2026-01-23
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+88.7
Score
AI commentary
Sentiment is mixed-to-constructive: consensus median (~$69) implies modest near-term upside, but a wide high/low spread signals event-driven volatility and divergent views across analysts [#SERP-1], [#SERP-3]. Near-term focus is on data and target revisions; long-term tone depends on commercialization evidence.
RankAlpha Sentiment AI - 2026-01-23
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-23eventPartnerships / licensing announcementsHigh impact
New collaborations or licenses could de-risk programs and add non-dilutive capital; timing is uncertain so a conservative window is used [#SERP-3].
2026-04-23catalystNear-term clinical data readoutsHigh impact
Upcoming mid-to-late stage readouts could re-rate shares; positive efficacy/safety would lift valuation while negative results would drive sharp downside [#SERP-1].
2027-01-23catalystRegulatory approvals and early commercializationHigh impact
Regulatory success and initial commercial uptake for lead indications would materially expand revenue and support multiple expansion; timing is multi-quarter [#SERP-2].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-23 • Updated nightlySource: Internal modelMethodology